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Abstract
Introduction: In this study, we aimed to determine the relationship between flow-mediated endothelium-
dependent vasodilatation (FMD) and carotid artery intima-media wall thickness (IMT), two surrogate markers of
atherosclerosis, in a series of Spanish patients with rheumatoid arthritis (RA) without clinically evident
cardiovascular (CV) disease.
Methods: One hundred eighteen patients who fulfilled the 1987 American College of Rheumatology classification
criteria for RA, had no history of CV disease and had at least one year of follow-up after disease diagnosis were
randomly selected. Brachial and carotid ultrasonography were performed to determine FMD and carotid IMT,
respectively.
Results: Carotid IMT values were higher and FMD percentages derived by performing ultrasonography were lower
in individuals with a long duration from the time of disease diagnosis. Patients with a disease duration ≤ 7 years
had significantly lower carotid IMT (mean ± SD) 0.69 ± 0.17 mm than those with long disease duration (0.81 ± 0.12
mm in patients with ≥ 20 years of follow-up). Also, patients with a long disease duration had severe endothelial
dysfunction (FMD 4.0 ± 4.0% in patients with disease duration from 14.5 to 19.7 years) compared with those with
shorter disease duration (FMD 7.4 ± 3.8% in patients with disease duration ≤ 7 years). Linear regression analysis
revealed that carotid IMT was unrelated to FMD in the whole sample of 118 patients. However, carotid IMT was
negatively associated with FMD when the time from disease diagnosis ranged from 7.5 to 19.7 years (P = 0.02).
Conclusions: In patients with RA without CV disease, endothelial dysfunction and carotid IMT increased with the
duration of RA. The association between FMD and carotid IMT values was observed only in patients with long
disease duration.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease associated with increased incidence of cardiovascu-
lar (CV) mortality [1,2]. This is the result of accelerated
atherosclerosis [3]. Because of the high incidence of CV
events observed in patients with RA, an important step
forward might be to identify high-risk individuals who
would benefit from active therapy to prevent clinical dis-
ease. In this regard, several noninvasive imaging techni-
ques offer clinicians a unique opportunity to study the
relationship of surrogate markers to the development of
atherosclerosis. Among them, ultrasound techniques
based on flow velocity and intimal thickness are consid-
ered efficient ways to measure subclinical atherosclerosis.
Using brachial artery ultrasonography assessment, we
and others have found the presence of endothelial dys-
function expressed by abnormal levels of flow-mediated
endothelium-dependent vasodilatation (FMD) in patients
without clinically evident CV disease who had either
long-standing RA [4] or early-onset RA [5]. Moreover,
increased carotid artery intima-media wall thickness
(IMT) and increased frequency of carotid plaques have
been described in RA patients with or without classic CV
risk factors compared to ethnically matched controls
[6-11]. Also, besides an association of carotid IMT with
markers of inflammation [12,13], the duration of the
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IMT [14] and the presence of carotid plaques [8,11]. This
is in accordance with data showing progression of carotid
IMT in RA patients with long-standing, severe disease
despite treatment with anti-TNF-a therapy [15]. Interest-
ingly, a recent observation disclosed that carotid IMT
may predict the development of CV events in patients
with RA [16].
Since FMD constitutes a physiologic assessment of
endothelial dysfunction and carotid IMT is an anatomic
structural measure of subclinical atherosclerosis, it is
l o g i c a lt h a tF M Dm i g h tb eam o r eu s e f u ld i a g n o s t i c
marker than carotid IMT in the early stages of the dis-
ease. In contrast, carotid IMT might be considered in
the assessment of CV risk among patients with long-
standing RA.
No relationship between carotid IMT and brachial
artery FMD was found in middle-aged men without a
history of CV disease who were considered to be at low
or intermediate risk for future CV events based on cur-
rent risk stratification algorithms [17]. However, because
of the increased risk of CV events, this may not be the
case for patients with long-standing RA.
Taking into consideration all of these factors together,
and based on the experience of our group in the study of
subclinical atherosclerosis not only in RA but also in
other chronic inflammatory rheumatic diseases using
ultrasound techniques [18-20], in the present study we
aimed to determine the relationship between FMD and
carotid IMT in RA patients without clinically evident CV
disease.
Materials and methods
Patients and study protocol
Between January 2008 and December 2009, a series of
118 patients attending the rheumatology outpatient clinic
of Hospital Xeral-Calde, Lugo, Spain, who fulfilled the
1987 American College of Rheumatology classification
criteria for RA [21] and had no history of CV disease and
but had at least one year of follow-up from their disease
diagnosis were randomly selected for ultrasonographic
assessment. To determine whether endothelial dysfunc-
tion was present, FMD was assessed by brachial ultraso-
nography as previously reported [18,22]. An FMD value
< 7% was considered pathologic, indicating the presence
of endothelial dysfunction [22]. Intraobserver variability
for FMD and NTG was 1.3% and 1.9%, respectively,
based on repeat brachial ultrasonography in 32 healthy
controls. Assessment of the endothelial function of
patients undergoing anti-TNF-a therapy was performed
24 to 48 hours before drug administration. Also, carotid
ultrasonography was performed to determine carotid
artery IMT. IMT was assessed in the right common caro-
tid artery as previously reported [19,22]. On the basis of a
second carotid ultrasonography performed in 20 RA
patients and 20 healthy controls within one week after
the first assessment, the correlation coefficient for carotid
IMT was 0.98. The main epidemiological data of this ser-
ies of patients are shown in Table 1. The patients’ written
consent was obtained according to the Declaration of
Helsinki, and the design of the work was approved by the
Ethics Committee of Galicia (Spain).
Statistical analysis
Quantitative variables are described using means and
standard deviations (SDs) and medians and interquartile
ranges (IQRs), and qualitative variables are described as
numbers and percentages. The relationship between car-
otid IMT (as a dependent variable) and FMD (as an inde-
pendent variable) was explored using linear regression,
adjusting for gender, age at the time of RA diagnosis and
years from RA disease diagnosis to ultrasonographic
assessment. To further explore this relationship, we
repeated the regression analysis by stratifying patients
into quartiles defined by the time from RA diagnosis to
ultrasonographic evaluation.
Results
Patients with RA were stratified into four quartiles accord-
ing to the time from disease diagnosis to ultrasonographic
assessment (Table 2). Following this procedure, we
observed that carotid IMT values were greater in indivi-
duals with a longer duration from disease diagnosis to
ultrasonographic assessment (P < 0.001). In this regard,
carotid IMT values were higher if time from RA diagnosis
was longer than its median (that is, > 14 years). With
respect to this observation, individuals with disease dura-
tion from RA diagnosis ≤ 7 years had significantly lower
carotid IMT wall thickness (0.69 ± 0.17 mm) than did
those with long disease duration (0.81 ± 0.12 mm in
Table 1 Main epidemiologic data for 118 patients with RA who underwent ultrasonography
a
Variable Mean ± SD or number of patients (%) Median (IQR)
Age at the time of the study, years 58.4 ± 12.9 59.5 (49 to 68.5)
Disease duration from RA diagnosis, years 13.8 ± 7.7 14 (7 to 19.7)
Women 89 (75.4%)
Rheumatoid factor-positive 96 (81.4%)
aRA: rheumatoid arthritis, SD: standard deviation, IQR: interquartile range.
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time of RA diagnosis). Likewise, FMD decreased as time
from RA diagnosis increased (P < 0.001). As shown in the
carotid artery ultrasonographic evaluation, individuals
with longer disease duration from disease diagnosis had
severe endothelial dysfunction (FMD 4.0 ± 4.0% in RA
patients with disease duration between 14.5 and 19.7 years
versus 3.3 ± 4.4% in those with disease duration ≥ 20
years) compared with RA patients who had shorter disease
duration (FMD 7.4 ± 3.8% in patients with disease dura-
tion ≤ 7 years).
To explore the relationship between FMD and carotid
IMT, linear regression analysis was performed. This ana-
lysis disclosed that carotid IMT was unrelated to FMD
endothelium-dependent vasodilatation in the whole sam-
ple of 118 patients (Table 3). However, when patients
with RA were stratified according to the time from dis-
ease diagnosis until the time of ultrasonography, carotid
IMT was negatively associated with FMD when the time
from disease diagnosis ranged from 7.5 to 19.7 years (P =
0.02). In patients included in this range of disease dura-
tion, the higher FMD percentages were associated with
thinner (that is, lower) carotid IMT values (Figure 1).
However, in patients with shorter disease duration (one
t os e v e ny e a r s )o rl o n g e rd i s e a s ed u r a t i o n( ≥ 20 years),
FMD and carotid IMT values remained unrelated
(Table 4).
Discussion
A series of cellular, molecular and pathophysiological
events occur during the progression of RA and may also
be involved first in endothelial dysfunction and later in
atherosclerosis [23]. A healthy endothelium prevents
adhesion of mononuclear cells. Inflammation promotes
endothelial cell activation, which is characterized by loss
of vascular integrity, increased expression of leukocyte
adhesion molecules such as selectins, vascular cell adhe-
sion molecule 1 and intercellular adhesion molecule 1
(ICAM-1); change in phenotype from antithrombotic to
thrombotic; production of several cytokines; and upre-
gulation of human leukocyte antigen molecules. All of
these changes allow endothelial cells to participate in
the inflammatory response. In this process, the increased
expression of adhesion molecules promotes the adher-
ence and migration of monocytes into the vessel wall.
Differentiation of monocytes into macrophages in the
intima and activation and further differentiation to form
cells characterize the development of early atherosclero-
tic lesions [24,25]. Continuous endothelial cell activa-
tion, manifested by increased levels of the adhesion
molecules soluble ICAM-1 and sE-selectin, is present in
patients with RA [26]. This endothelial cell activation
subsequently leads to endothelial dysfunction, which is
an important event in early atherogenesis and also con-
tributes to the development of clinical features in the
later stages of the vascular disease, including the
Table 2 Distribution of carotid IMT and FMD in RA patients stratified into four quartiles according to time from
disease diagnosis to ultrasonography
a
Time from RA diagnosis to ultrasonography Carotid IMT (mm) mean ± SD FMD (%) mean ± SD
Quartile 1, one to seven years 0.69 ± 0.17 7.4 ± 3.8
Quartile 2, 7.5 to 14 years 0.68 ± 0.16 6.6 ± 4.6
Quartile 3, 14.5 to 19.7 years 0.84 ± 0.24 4.0 ± 4.0
Quartile 4, 20 to 38 years 0.81 ± 0.12 3.3 ± 4.4
P value < 0.001 < 0.001
aCarotid IMT: carotid intima-media wall thickness, FMD: flow-mediated endothelium-dependent vasodilatation, RA: rheumatoid arthritis.
Table 3 Regression analysis between carotid IMT and
FMD
a
Variable Correlation coefficient (95% confidence interval) P value
FMD
b -0.003 (-0.009 to 0.003) 0.35
aCarotid IMT: carotid intima-media wall thickness, FMD: flow-mediated
endothelium-dependent vasodilatation, RA: rheumatoid arthritis;
bAdjusted for
gender, age at the time of disease diagnosis and years from RA diagnosis to
ultrasonography assessment.
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Figure 1 Scatterplot illustrating the relationships between FMD
and carotid IMT in patients with RA and disease duration
ranging between 7 and 20 years derived using linear
regression analysis.
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Kerekes et al.[ 2 8 ]s h o w e dt h a td i s e a s ed u r a t i o nw a s
associated with impaired FMD and several biomarkers
of inflammation. Although in the present study we
found no impairment of endothelial function as deter-
mined on the basis of brachial FMD in patients with < 7
years’ disease duration, longer disease duration, particu-
larly > 14 years, was associated with severe endothelial
dysfunction. In keeping with this observation, Södergren
et al. [29] found no impairment in endothelial function,
measured as FMD, among patients with newly diag-
nosed RA compared with controls.
With regard to carotid ultrasonography, it is known
that a common carotid artery IMT ≥ 0.60 mm is a mar-
ker of atherosclerosis [30,31]. In addition, both carotid
artery IMT > 0.90 mm and the presence of carotid pla-
ques are considered to be expression of subclinical
organ damage and factors influencing CV prognosis in
the general population [32]. Interestingly, a recent meta-
analysis demonstrated an increased carotid IMT in
patients with early RA [33]. Although the increase in
carotid IMT in this meta-analysis was much lower than
expected in view of the almost doubled CV risk in RA
patients [33], carotid IMT was proven to predict the
development of CV events in RA patients [16]. Because
of that finding, the presence of abnormally high carotid
IMT values should be raise clinical suspicions as a sign
of the development of CV complications in these
patients. In the present study, we observed that indivi-
duals with long disease duration (> 14 years) had abnor-
mally high carotid IMT values. With respect to this
observation, on the basis of 631 consecutive RA
patients, del Rincón et al. [14] showed that IMT
increases per unit of age in proportion to RA duration.
In del Rincón et al.’s study [14], carotid IMT increased
from 0.154 mm/10 years among patients with RA for ≤
7 years to 0.295 mm/10 years among patients with RA
for ≥ 20 years.
In line with the above findings, using electron-beam
computed tomography to measure the extent of coron-
ary artery calcification, Chung et al. [34] found that cor-
onary-artery calcification occurred more frequently in
patients with established RA than in patients with early
RA and controls. A question that needs to be answered
is whether carotid ultrasonography and brachial FMD
should routinely be performed in all patients with RA to
improve CV risk management. With respect to this
question, carotid IMT was found to be an independent
predictor of vascular events in high-risk individuals
w i t h o u tR Ai nw h o mr i s kf a c t o r sw e r em a n a g e dc l i n i -
cally [35]. Since the risk of CV disease is increased in
patients with RA, carotid ultrasound might be a poten-
tial additional tool for stratifying CV risk in patients
with RA [22]. In this regard, a recent study by Evans
et al. [36] showed that the presence of carotid plaques
in both internal carotid arteries following carotid ultra-
sonography nearly quadrupled the incidence of new
acute coronary syndromes in patients with RA com-
pared with those in RA patients without carotid plaques.
On the hand, impaired FMD of the brachial artery due
to endothelial dysfunction has been associated with both
CV risk factors and future CV morbidity and mortality
in the general population [37]. In addition, endothelial
dysfunction manifested by impaired FMD was observed
in both long-standing RA patients [4] and early-onset
RA patients [5] without clinically evident CV disease.
These observations support a potential role of FMD in
establishing the presence of endothelial dysfunction as a
subclinical marker of atherosclerotic disease in RA.
They may also provide a basis for the association
between RA and atherosclerotic disease.
Of main clinical relevance may be the improvement in
endothelial function observed in patients with RA follow-
ing treatment with TNF-a blockers [38-40] or rituximab
[41,42]. However, the beneficial effect of the TNF-a
antagonist infliximab on endothelial dysfunction seems
to be only temporary [43]. Conflicting results have been
described regarding the effects of biologic agents on caro-
tid atherosclerosis [44]. In this regard, while some
patients showed significant improvement in carotid IMT
following TNF-a blocker therapy [45], others did not
experience reduction of IMT following treatment with
these drugs [15,40,46].
Previous observations showed no relationship between
carotid IMT and brachial artery FMD in middle-aged
men at low and intermediate risk of experiencing future
CV events [17]. However, the situation might not be the
same in patients with long-standing RA. Therefore, we
aimed to determine the relationship between both tech-
niques in patients with RA. On the basis of linear
Table 4 Regression analysis between carotid IMT and FMD stratified by disease duration from the time of RA
diagnosis until ultrasonography assessment
a
Time from RA diagnosis until ultrasonography Correlation coefficient (95% confidence interval) P value
Quartile 1, one to seven years -0.003 (-0.019 to 0.013) 0.82
Quartiles 2 and 3, 7.5 to 19.7 years -0.012 (-0.021 to -0.003) 0.02
Quartile 4, 20 to 38 years 0.008 (-0.003 to 0.019) 0.27
aCarotid IMT: carotid intima-media wall thickness, FMD: flow-mediated endothelium-dependent vasodilatation, RA: rheumatoid arthritis. Data are adjusted for
gender, age at time of diseaseand time from RA diagnosis until ultrasonography.
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unrelated to FMD in the whole sample of 118 patients.
This observation was also in keeping with another study
performed in elderly individuals that showed no correla-
tion between brachial FMD and carotid IMT [47]. How-
ever, our data suggest that in patients with disease
duration ranging between from 7.5 to 19.7 years, carotid
IMT is negatively associated with brachial FMD.
Conclusions
In summary, our results reinforce the importance of dis-
ease duration in the development of atherosclerosis in
patients with RA. Brachial FMD and carotid IMT may
indicate distinct and independent stages in the complex
pathways leading to accelerated atherosclerosis in
patients with RA.
Abbreviations
CV: cardiovascular; IMT: intima-media thickness; IQR: interquartile range; FMD:
endothelium-dependent flow-mediated vasodilatation; RA: rheumatoid
arthritis; SD: standard deviation.
Acknowledgements
This study was supported by “Fondo de Investigaciones Sanitarias” grants
PI06-0024 and PS09/00748 (Spain). This work was partially supported by the
RETICS Program, RD08/0075 (RIER), from “Instituto de Salud Carlos III” (ISCIII).
Author details
1Cardiology Division, Hospital Xeral-Calde, c/Dr. Ochoa s/n, Lugo E-27004,
Spain.
2Department of Epidemiology and Computational Biology, School of
Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública
(CIBERESP), IFIMAV, Avenida Herrera Oria s/n, E-39011 Santander, Spain.
3Department of Rheumatology, Hospital Universitario Marqués de Valdecilla,
IFIMAV, Avenida de Valdecilla s/n, E-39008, Santander, Spain.
Authors’ contributions
CGJ performed the ultrasonographic studies, participated in the design of
the study and helped to draft the manuscript. JL participated in the design
of the study and data analysis and helped to draft the manuscript. MAGG
made substantial contributions to the conception and design of the study,
the acquisition of data and the coordination of the study. All authors read
and approved the final version of the manuscript to be published.
Competing interests
The authors declare that they have no competing interests.
Received: 8 March 2011 Revised: 17 May 2011 Accepted: 22 June 2011
Published: 22 June 2011
References
1. Goodson N, Marks J, Lunt M, Symmons D: Cardiovascular admissions and
mortality in an inception cohort of patients with rheumatoid arthritis
with onset in the 1980s and 1990s. Ann Rheum Dis 2005, 64:1595-1601.
2. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE,
Stampfer MJ, Curhan GC: Cardiovascular morbidity and mortality in
women diagnosed with rheumatoid arthritis. Circulation 2003,
107:1303-1307.
3. González-Gay MA, González-Juanatey C, Martin J: Rheumatoid arthritis: a
disease associated with accelerated atherogenesis. Semin Arthritis Rheum
2005, 35:8-17.
4. González-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J,
Vidan J, Hajeer AH, Ollier WE, Mattey DL, González-Gay MA: HLA-DRB1
status affects endothelial function in treated patients with rheumatoid
arthritis. Am J Med 2003, 114:647-652.
5. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, Pirro M,
Shoenfeld Y, Schillaci G, Mannarino E: Endothelial dysfunction in young
patients with rheumatoid arthritis and low disease activity. Ann Rheum
Dis 2004, 63:31-35.
6. Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, Ishimura E,
Inui K, Yutani Y, Miki T, Shoji T, Nishizawa Y: Increased thickness of the
arterial intima-media detected by ultrasonography in patients with
rheumatoid arthritis. Arthritis Rheum 2002, 46:1489-1497.
7. Park YB, Ahn CW, Choi HK, Lee SH, In BH, Lee HC, Nam CM, Lee SK:
Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained
by carotid ultrasound. Arthritis Rheum 2002, 46:1714-1719.
8. González-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C,
González-Gay MA: Increased prevalence of severe subclinical
atherosclerotic findings in long-term treated rheumatoid arthritis
patients without clinically evident atherosclerotic disease. Medicine
(Baltimore) 2003, 82:407-413.
9. Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJ: Rheumatoid arthritis and
macrovascular disease. Rheumatology (Oxford) 2003, 42:292-297.
10. Abu-Shakra M, Polychuck I, Szendro G, Bolotin A, Jonathan BS, Flusser D,
Buskila D, Sukenik S: Duplex study of the carotid and femoral arteries of
patients with rheumatoid arthritis: a controlled study. Semin Arthritis
Rheum 2005, 35:18-23.
11. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD,
Sammaritano L, Devereux RB, Schwartz JE, Levine DM, Salmon JE:
Preclinical carotid atherosclerosis in patients with rheumatoid arthritis.
Ann Intern Med 2006, 144:249-256.
12. del Rincón I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A:
Association between carotid atherosclerosis and markers of
inflammation in rheumatoid arthritis patients and healthy subjects.
Arthritis Rheum 2003, 48:1833-1840.
13. González-Gay MA, González-Juanatey C, Piñeiro A, Garcia-Porrua C, Testa A,
Llorca J: High-grade C-reactive protein elevation correlates with
accelerated atherogenesis in patients with rheumatoid arthritis. J
Rheumatol 2005, 32:1219-1223.
14. del Rincón I, O’Leary DH, Freeman GL, Escalante A: Acceleration of
atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis
2007, 195:354-360.
15. González-Juanatey C, Llorca J, Garcia-Porrua C, Martin J, González-Gay MA:
Effect of anti-tumor necrosis factor α therapy on the progression of
subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum
2006, 55:150-153.
16. González-Juanatey C, Llorca J, Martin J, González-Gay MA: Carotid intima-
media thickness predicts the development of cardiovascular events in
patients with rheumatoid arthritis. Semin Arthritis Rheum 2009, 38:366-371.
17. Yan RT, Anderson TJ, Charbonneau F, Title L, Verma S, Lonn E: Relationship
between carotid artery intima-media thickness and brachial artery flow-
mediated dilation in middle-aged healthy men. J Am Coll Cardiol 2005,
45:1980-1986.
18. González-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A,
Garcia-Porrua C, Martin J, González-Gay MA: Endothelial dysfunction in
psoriatic arthritis patients without clinically evident cardiovascular
disease or classic atherosclerosis risk factors. Arthritis Rheum 2007,
57:287-293.
19. González-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, González-
Gay MA: High prevalence of subclinical atherosclerosis in psoriatic
arthritis patients without clinically evident cardiovascular disease or
classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:1074-1080.
20. González-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Dierssen T,
Vaqueiro I, Blanco R, Martin J, Llorca J, González-Gay MA: The high
prevalence of subclinical atherosclerosis in patients with ankylosing
spondylitis without clinically evident cardiovascular disease. Medicine
(Baltimore) 2009, 88:358-365.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS,
Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM,
Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The
American Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
22. González-Gay MA, González-Juanatey C, Vazquez-Rodriguez TR, Martin J,
Llorca J: Endothelial dysfunction, carotid intima-media thickness, and
accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum
2008, 38:67-70.
González-Juanatey et al. Arthritis Research & Therapy 2011, 13:R101
http://arthritis-research.com/content/13/3/R101
Page 5 of 623. González-Gay MA, González-Juanatey C, Martin J: Inflammation and
endothelial dysfunction in rheumatoid arthritis. Clin Exp Rheumatol 2006,
24:115-117.
24. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation
2002, 105:1135-1143.
25. Bijl M: Endothelial activation, endothelial dysfunction and premature
atherosclerosis in systemic autoimmune diseases. Neth J Med 2003,
61:273-277.
26. Wållberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapää-
Dahlqvist S: Activation of the immune system and inflammatory activity
in relation to markers of atherothrombotic disease and atherosclerosis
in rheumatoid arthritis. J Rheumatol 2002, 29:875-882.
27. Vita JA, Keaney JF Jr: Endothelial function: a barometer for cardiovascular
risk? Circulation 2002, 106:640-642.
28. Kerekes G, Szekanecz Z, Dér H, Sándor Z, Lakos G, Muszbek L, Csipö I,
Sipka S, Seres I, Paragh G, Kappelmayer J, Szomják E, Veres K, Szegedi G,
Shoenfeld Y, Soltész P: Endothelial dysfunction and atherosclerosis in
rheumatoid arthritis: a multiparametric analysis using imaging
techniques and laboratory markers of inflammation and autoimmunity. J
Rheumatol 2008, 35:398-406.
29. Södergren A, Karp K, Boman K, Eriksson C, Lundström E, Smedby T,
Söderlund L, Rantapää-Dahlqvist S, Wållberg-Jonsson S: Atherosclerosis in
early rheumatoid arthritis: very early endothelial activation and rapid
progression of intima media thickness. Arthritis Res Ther 2010, 12:R158.
30. Veller MG, Fisher CM, Nicolaides AN, Renton S, Geroulakos G, Stafford NJ,
Sarker A, Szendro G, Belcaro G: Measurement of the ultrasonic intima-
media complex thickness in normal subjects. J Vasc Surg 1993,
17:719-725.
31. Belcaro G, Nicolaides AN, Ramaswami G, Cesarone MR, De Sanctis M,
Incandela L, Ferrari P, Geroulakos G, Barsotti A, Griffin M, Dhanjil S,
Sabetai M, Bucci M, Martines G: Carotid and femoral ultrasound
morphology screening and cardiovascular events in low risk subjects: a
10-year follow-up study (the CAFES-CAVE study). Atherosclerosis 2001,
156:379-387.
32. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G,
Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L,
Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J,
De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C,
Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M,
Widimsky P, Management of Arterial Hypertension of the European Society
of Hypertension, European Society of Cardiology, et al: Guidelines for the
Management of Arterial Hypertension: The Task Force for the
Management of Arterial Hypertension of the European Society of
Hypertension (ESH) and of the European Society of Cardiology (ESC). J
Hypertens 2007, 25:1105-1187, A published erratum appears in J Hypertens
2007, 25:1749.
33. van Sijl AM, Peters MJ, Knol DK, de Vet HC, González-Gay MA, Smulders YM,
Dijkmans BA, Nurmohamed MT: Carotid intima media thickness in
rheumatoid arthritis as compared to control subjects: a meta-analysis.
Semin Arthritis Rheum 2011, 40:389-397.
34. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, Pincus T,
Avalos I, Stein CM: Increased coronary-artery atherosclerosis in
rheumatoid arthritis: relationship to disease duration and cardiovascular
risk factors. Arthritis Rheum 2005, 52:3045-3053.
35. Kitagawa K, Hougaku H, Yamagami H, Hashimoto H, Itoh T, Shimizu Y,
Takahashi D, Murata S, Seike Y, Kondo K, Hoshi T, Furukado S, Abe Y,
Yagita Y, Sakaguchi M, Tagaya M, Etani H, Fukunaga R, Nagai Y,
Matsumoto M, Hori M, OSACA2 Study Group: Carotid intima-media
thickness and risk of cardiovascular events in high-risk patients: results
of the Osaka Follow-Up Study for Carotid Atherosclerosis 2 (OSACA2
Study). Cerebrovasc Dis 2007, 24:35-42.
36. Evans MR, Escalante A, Battafarano DF, Freeman GL, O’Leary DH, del
Rincón I: Carotid atherosclerosis predicts incident acute coronary
syndromes in rheumatoid arthritis. Arthritis Rheum 2011, 63:1211-1120.
37. Ter Avest E, Stalenhoef AF, de Graaf J: What is the role of non-invasive
measurements of atherosclerosis in individual cardiovascular risk
prediction? Clin Sci (Lond) 2007, 112:507-516.
38. Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Béchir M,
Spieker LE, Neidhart M, Michel BA, Gay RE, Lüscher TF, Gay S, Ruschitzka F:
Anti-tumor necrosis factor-α treatment improves endothelial function in
patients with rheumatoid arthritis. Circulation 2002, 106:2184-2187.
39. González-Juanatey C, Llorca J, Sanchez-Andrade A, Garcia-Porrua C, Martin J,
González-Gay MA: Short-term adalimumab therapy improves endo-thelial
function in patients with rheumatoid arthritis refractory to infliximab.
Clin Exp Rheumatol 2006, 24:309-312.
40. Sidiropoulos PI, Siakka P, Pagonidis K, Raptopoulou A, Kritikos H, Tsetis D,
Boumpas DT: Sustained improvement of vascular endothelial function
during anti-TNFα treatment in rheumatoid arthritis patients. Scand J
Rheumatol 2009, 38:6-10.
41. González-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-
Quiroga H, González-Gay MA: Short-term improvement of endothelial
function in rituximab-treated rheumatoid arthritis patients refractory to
tumor necrosis factor α blocker therapy. Arthritis Rheum 2008,
59:1821-1824.
42. Kerekes G, Soltész P, Dér H, Veres K, Szabó Z, Végvári A, Szegedi G,
Shoenfeld Y, Szekanecz Z: Effects of rituximab treatment on endothelial
dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid
arthritis. Clin Rheumatol 2009, 28:705-710.
43. González-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J,
González-Gay MA: Active but transient improvement of endothelial
function in rheumatoid arthritis patients undergoing long-term
treatment with anti-tumor necrosis factor α antibody. Arthritis Rheum
2004, 51:447-450.
44. Szekanecz Z, Kerekes G, Soltész P: Vascular effects of biologic agents in
RA and spondyloarthropathies. Nat Rev Rheumatol 2009, 5:677-684.
45. Del Porto F, Laganà B, Lai S, Nofroni I, Tinti F, Vitale M, Podestà E,
Mitterhofer AP, D’Amelio R: Response to anti-tumour necrosis factor α
blockade is associated with reduction of carotid intima-media thickness
in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007,
46:1111-1115.
46. Wong M, Oakley SP, Young L, Jiang BY, Wierzbicki A, Panayi G,
Chowienczyk P, Kirkham B: Infliximab improves vascular stiffness in
patients with rheumatoid arthritis. Ann Rheum Dis 2009, 68:1277-1284.
47. Yeboah J, Burke GL, Crouse JR, Herrington DM: Relationship between
brachial flow-mediated dilation and carotid intima-media thickness in an
elderly cohort: the Cardiovascular Health Study. Atherosclerosis 2008,
197:840-845.
doi:10.1186/ar3382
Cite this article as: González-Juanatey et al.: Correlation between
endothelial function and carotid atherosclerosis in rheumatoid arthritis
patients with long-standing disease. Arthritis Research & Therapy 2011 13:
R101.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
González-Juanatey et al. Arthritis Research & Therapy 2011, 13:R101
http://arthritis-research.com/content/13/3/R101
Page 6 of 6